OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
November 24, 2020
FDA granted fast track designation for AB201, a small recombinant protein that is a potent, selective inhibitor of tissue factor, for the potential treatment of COVID-19.
The EC’s approval was based on positive results from a Phase III clinical trial that demonstrated a statistically significant and clinically meaningful improvement in patients compared to chemotherapy.
The EC’s approval comes after positive results from seven Phase II and III randomized, active-controlled, multi-center studies.
November 23, 2020
The companies have formed a long-term manufacturing agreement to accelerate the global supply for Lilly’s COVID-19 antibody therapeutics.
An independent data safety monitoring board found that clinical trial data demonstrated that the vaccine candidate met its primary endpoint and demonstrated protection from COVID-19.
November 19, 2020
Researchers concluded that the nasal spray should catch and coat the virus inside the nose, preventing it from spreading throughout the body, and it is then removed by nose-blowing or swallowing.
The first of its kind, Lycagel is made up of pea starch technology.
November 18, 2020
Pfizer and BioNTech’s BNT162b2 shows efficacy of 95%; the companies plan to submit a request, within days, to FDA for an EUA.
November 17, 2020
Moderna’s COVID-19 vaccine candidate can be distributed using widely available vaccine delivery and storage infrastructure.
November 16, 2020
The companies will work together on research activities through to the selection of a preclinical candidate, after which Roche will handle further development and global commercialization.